NAMSA Experience With Cardiovascular Devices

NAMSA Preclinical Experience with Cardiovascular Devices

Return to top

NAMSA’s preclinical services provide manufacturers with a comprehensive, globally accessible foundation for evaluating the safety and performance of cardiovascular technologies. Backed by deep therapeutic expertise and GLP compliant, AAALAC accredited facilities across the US and Europe, our teams design and execute studies that bridge preclinical insights to clinical success—accelerating development while supporting strong, decision ready data. To explore our full capabilities and facility resources, visit our Preclinical page.

Preclinical services we offer:

Non-GLP Studies | GLP Studies | Pathology/Histopathology | Bioskills/Physician Training | See All

Preclinical Expertise: Cardiovascular Models, Faster Translation, Stronger Submissions

NAMSA supports Cardiovascular innovators from concept through clearance by aligning preclinical execution with regulatory strategy from the start. Our consulting teams help:

• Define efficient, indication‑specific cardiovascular device testing plans
• Support FDA interactions (including pre‑submission strategy and responses) and engagement with other regulatory authorities
• Identify the least‑burdensome path to approval, ensuring preclinical data supports regulatory submissions and first‑in‑human readiness

Our GLP‑aligned preclinical platform is purpose‑built for cardiovascular devices, combining expertise in cardiovascular physiology, hemodynamics, biomaterials, and device–tissue interactions. We design studies that capture clinically relevant functional, behavioral, and histopathological endpoints, supporting early feasibility through GLP safety evaluations and producing data packages regulators expect to see.

NAMSA offers a broad and flexible range of cardiovascular specific animal models, selecting the most appropriate approach for each device and indication, and developing novel models in collaboration with sponsors when needed. Our experience spans interventional cardiology, structural heart, cardiac rhythm management, peripheral vascular applications, stents, transcatheter valves, embolic protection devices, vascular grafts, drug device combinations, or ablation technologies. These programs are supported across both small and large animal models, including pigs, sheep, goats, dogs, rabbits, and rats.

Why Cardiovascular Sponsors Choose NAMSA

• Preclinical strategies designed with the regulatory end goal in mind, not in isolation
• Deep experience across interventional, structural heart, and vascular technologies
• Ability to avoid common development traps that delay submissions and first‑in‑human studies
• Integrated consulting, preclinical, clinical, and testing expertise for faster, more efficient progression
• More than 50 years of medical device experience and regulator‑recognized reports that build confidence and trust

State of the Art Facilities in the US and Europe

With four strategically located preclinical facilities, two in the United States and two in Europe, NAMSA delivers globally accessible, world‑class environments purpose‑built for cardiovascular device evaluation. Each location is equipped to support a full continuum of preclinical research needs, enabling consistent study execution, rigorous data quality and seamless collaboration across regions. Learn More About our Equipment and Facilities.

Selected Preclinical Projects for Cardiovascular Devices

NAMSA brings extensive experience delivering both GLP and non‑GLP preclinical programs for Cardiovascular devices, supporting everything from early feasibility and proof‑of‑concept work to pivotal safety and performance studies. Our teams have conducted hundreds of cardio-focused preclinical projects per year across four global sites, leveraging deep model expertise and decades of in vivo experience to generate high‑quality, decision‑driving data. Whether accelerating early iteration through fast‑paced non‑GLP studies or executing robust GLP programs aligned with regulatory expectations, NAMSA provides the scientific rigor, procedural excellence, and translational insight needed to advance innovative cardiovascular devices toward clinical readiness.

NAMSA Clinical Experience with Cardiovascular Devices

Return to top

NAMSA’s clinical research teams provide end‑to‑end support across every stage of clinical evidence generation for medical device development, from first‑in‑human through pivotal, human factors, and post‑market studies. Backed by global expertise, rigorous SOPs, and a fully integrated suite of services, we help sponsors generate high‑quality clinical evidence, streamline regulatory submissions, and accelerate time to commercialization. To explore our full clinical capabilities and global support model, visit our Clinical page.

Clinical research services we offer:

Study Design | Trial Management | Data Management | Biostatistics | Medical Writing | See All

NAMSA Expertise with Cardiovascular Devices

Cardiovascular device development is among the most demanding in all of MedTech: high-risk populations, complex endpoints, and intense regulatory scrutiny. NAMSA was built to help you navigate these challenges. Our cardiovascular team combines decades of hands-on trial execution with the regulatory, biostatistical, and clinical study strategy depth that Class III cardiovascular device manufacturers need from a single, accountable partner.

Clinical Expertise

Decades of cardiovascular trial experience, built into every project team

Cardiovascular clinical studies account for roughly 40% of NAMSA’s entire clinical study portfolio. That is not a coincidence — it reflects more than 55 years of focused investment in this therapeutic area. When you work with NAMSA, your study team is not staffed with generalists who rotate across therapeutic areas. Your clinical study manager, clinical research associates, data managers, safety monitors, and biostatisticians are professionals who run cardiovascular device trials every single day.

Site Network

A cardiovascular site network built for high risk, complex, difficult-to-enroll cardiovascular studies

Cardiovascular device trials fail on enrollment, not on science. Investigator sites that look good on paper often underperform because they lack scheduling flexibility, imaging infrastructure, or patient referral pipelines your study needs. NAMSA’s site qualification process is built specifically for cardiovascular complexity, finding the right site and the right investigator for you. We know which centers can execute, and we manage them relentlessly once they’re activated.

KOL Network

Cardiovascular KOLs who don’t just advise, they actively shape regulatory outcomes and clinical strategy

NAMSA’s cardiovascular Key Opinion Leaders are embedded in the work. They help sponsors refine trial strategy, anticipate FDA questions before they become deficiency letters, and connect programs to the broader cardiovascular clinical community.

End-to-End Clinical Research

One partner, one accountable team, from first protocol draft to final clinical study report

Cardiovascular sponsors who split their program across multiple vendors, one for study design, another for site management, another for biostatistics, another for data management, pay for it in miscommunication, rework, and timeline slippage. NAMSA provides every service a cardiovascular clinical program needs, integrated under a single project team with a single point of accountability. No hand-offs. No gaps. No vendor finger-pointing when something needs fixing.

Selected Clinical Research Projects for Cardiovascular Devices

Our global clinical teams provide flexible support models, whether sponsors need targeted, à la carte services like monitoring, biostatistics, data management, imaging core lab, CEC/DSMB oversight, or fully comprehensive, end‑to‑end clinical trial execution. This depth of expertise has enabled NAMSA to support hundreds of cardiovascular clinical studies across multiple geographies and study types, including first‑in‑human, pivotal, human factors, and post‑market projects such as PMCF studies. To learn more about how our clinical outsourcing models can accelerate your program, visit our outsourcing and Functional Service Provider page.

NAMSA Experience Testing Cardiovascular Devices

Return to top

NAMSA is the pioneer of the medical device testing industry and continues to serve as the global leader for reliable medical device testing services. We have developed a reputation for excellence in biocompatibility, analytical chemistry, microbiology, and sterility testing, and every year more than 3,000 medical device companies trust us to ensure the safety and compliance of their devices.

Testing services we offer:

Biocompatibility Testing | Microbiological Testing | Sterility Testing | See All

Types of Tests We Conduct on Cardiovascular Devices

For cardiovascular devices, particularly implantable, blood‑contacting, or long‑term systems, NAMSA delivers integrated safety evaluations across biocompatibility, chemical characterization, microbiology, and sterility, aligned with the unique risks of the cardiovascular system.

• Biocompatibility evaluations address hemocompatibility, thrombogenicity, and tissue response for stents, catheters, grafts, valves, and structural heart devices, in alignment with ISO 10993 expectations.
• Chemical characterization programs define material composition, identify extractables and leachables, and support long‑term material stability for devices exposed to continuous blood flow.
• Microbiology services mitigate contamination risk through tailored bioburden and endotoxin strategies designed for complex lumens and vascular pathways.
• Sterility expertise supports robust sterilization validation approaches aligned with cardiovascular implant use and regulatory expectations.

Together, these capabilities provide a cardio‑focused testing strategy that reduces risk, supports regulatory expectations, and accelerates progress toward clinical use.

Compliance and Consulting Experience With Cardiovascular Devices

Return to top

From biological safety plans to FDA strategy and support, NAMSA has deep expertise in medical device compliance. Our extensive team of QA/RA and biological safety consultants, medical writers, scientists and market research experts all have first-hand experience with medical device industry manufacturers. They understand how to balance the benefit-risk ratio with the practicalities of regulatory compliance. Because NAMSA performs preclinical studies, clinical research and testing on thousands of medical devices and IVDs each year, our consultants come to each project with a well-informed sense of what the US FDA, European Notified Bodies and other national regulators expect.

Selected compliance services we offer:

US FDA Compliance |  EU MDR/IVDR Compliance | Biological Safety Consulting | Global Compliance | See All

Premarket Strategy to Postmarket Support

NAMSA’s compliance services are designed to guide manufacturers through the full spectrum of global regulatory requirements, with a strong emphasis on submission strategy and readiness. Our regulatory experts, including former FDA and EU Notified Body staff, help clients develop clear, efficient pathways for 510(k), PMA, De Novo, IDE, MDR/IVDR, and international submissions, ensuring documentation, clinical evidence, and risk management plans align with regulator expectations. From early strategic planning through post‑market support, we provide the insight, structure, and cross‑functional alignment needed to navigate complex compliance landscapes and achieve timely, confident market entry.